Phaseline

Companies › HiFiBiO Therapeutics

HiFiBiO Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HFB200301–Phase 1Gastric CancerDec 2026
HFB200603–Phase 1Renal Cell CarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05789069HFB200603Phase 1Renal Cell CarcinomaOncologyDec 2026
NCT05238883HFB200301Phase 1Gastric CancerOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.